The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Pharmacotherapy for Neuropathic Pain: A Review
Open accessAbstract
Neuropathic pain, comprising a range of heterogeneous conditions, is often severe and difficult to manage, and this may result in a chronic condition that negatively affects the overall functioning and quality of life in patients. The pharmacotherapy of neuropathic pain is challenging and for many patients effective treatment is lacking; therefore, evidence-based recommendations are essential. Currently, there is general agreement on which drugs are appropriate for the first-line treatment of neuropathic pain, whereas debate continues regarding second- and third-line treatments. First-line drugs for neuropathic pain include antidepressants (tricyclic antidepressants and serotonin-noradrenaline reuptake inhibitors) and anticonvulsants acting at calcium channels (pregabalin and gabapentin). Second- and third-line drugs for neuropathic pain include topical lidocaine and opioids. Although efficacious in the treatment of neuropathic pain, opioids are not considered to be a first choice because of adverse drug reactions and, more recently, because of concerns about abuse, diversion, and addiction. A clear understanding of the mechanism of action of currently available drugs is an essential step towards an effective clinical approach that aims to tailor therapies both to the specific neuropathic disease and to the needs of an individual patient. This review provides an overview of current drugs available for the treatment of neuropathic pain with an emphasis on their mechanism of action. FUNDING: Pfizer, Italy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702 · cited 1×
“When considering the inherent limitations that are introduced when large amounts of homogenous studies are combined [2, 3], emphasis needs to be placed on guidelines that incorporate practical recommendations made on clinically based evidence.”
BackgroundPharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., Gilron, I., Haanpää, M., Hansson, P., Jensen, T. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70251-0 · Cited by 3,980 · cited 5×
“SNRIs have been proven to be efficacious in several neuropathic conditions including painful polyneuropathy, post-herpetic neuralgia, painful diabetic neuropathy, and low back pain [5].”
BackgroundInfluentialCDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6501e1 · Cited by 2,697
How to increase value and reduce waste when research priorities are set
Chalmers, I., Bracken, M. B., Djulbegovic, B., Garattini, S., Grant, J., Gülmezoglu, A. M., Howells, D. W., Ioannidis, J. P. A., & Oliver, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62229-1 · Cited by 1,436
Dworkin, R. H., O'Connor, A. B., Audette, J., Baron, R., Gourlay, G. K., Haanpää, M. L., Kent, J. L., Krane, E. J., LeBel, A. A., Levy, R. M., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0649 · Cited by 1,325
Long-term opioid management for chronic noncancer pain
Noble, M., Treadwell, J. R., Tregear, S. J., Coates, V. H., Wiffen, P. J., Akafomo, C., Schoelles, K. M., & Chou, R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006605.pub2 · Cited by 735
A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin
Bockbrader, H. N., Wesche, D., Miller, R., Chapel, S., Janiczek, N., & Burger, P. (2010) · Clinical Pharmacokinetics · doi:10.2165/11536200-000000000-00000 · Cited by 690
Moore, R. A., & McQuay, H. J. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1782 · Cited by 377
Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights
Kremer, M., Salvat, E., Muller, A., Yalcin, I., & Barrot, M. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.06.057 · Cited by 312
Combination pharmacotherapy for the treatment of neuropathic pain in adults
Chaparro, L. E., Wiffen, P. J., Moore, R. A., & Gilron, I. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008943.pub2 · Cited by 310
Stahl, S. M., Porreca, F., Taylor, C. P., Cheung, R., Thorpe, A. J., & Clair, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.04.001 · Cited by 277
Peltier, A., Goutman, S. A., & Callaghan, B. C. (2014) · BMJ · doi:10.1136/bmj.g1799 · Cited by 218
Adverse Effects Associated with Non-opioid and Opioid Treatment in Patients with Chronic Pain
Labianca, R., Sarzi-Puttini, P., Zuccaro, S. M., Cherubino, P., Vellucci, R., & Fornasari, D. (2012) · Clinical Drug Investigation · doi:10.2165/11630080-000000000-00000 · Cited by 201
Self-citationTricyclic antidepressants as long-acting local anesthetics
Sudoh, Y., Cahoon, E. E., Gerner, P., & Wang, G. K. (2003) · Pain · doi:10.1016/s0304-3959(02)00375-5 · Cited by 153
Tapentadol in Pain Management: A μ-Opioid Receptor Agonist and Noradrenaline Reuptake Inhibitor
Hartrick, C. T., & Rozek, R. J. (2011) · CNS Drugs · doi:10.2165/11589080-000000000-00000 · Cited by 138
Clinical practice guidelines for the management of neuropathic pain: a systematic review
Deng, Y.-K., Luo, L., Hu, Y., Fang, K., & Liu, J. (2015) · BMC Anesthesiology · doi:10.1186/s12871-015-0150-5 · Cited by 118
Sodium channels and pain: from toxins to therapies
Cardoso, F. C., & Lewis, R. J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13962 · Cited by 109
Takeuchi, Y., Takasu, K., Ono, H., & Tanabe, M. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.08.013 · Cited by 94
Bohren, Y., Tessier, L., Megat, S., Petitjean, H., Hugel, S., Daniel, D., Kremer, M., Fournel, S., Hein, L., Schlichter, R., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.08.012 · Cited by 83
Frieden, T. R. (2016) · MMWR Supplements · doi:10.15585/mmwr.su6503a1 · Cited by 80
Doxepin's effects on chronic pain and depression: a controlled study.
Hameroff, S. R., Weiss, J. L., Lerman, J. C., Cork, R. C., Watts, K. S., Crago, B. R., Neuman, C. P., Womble, J. R., & Davis, T. P. (1984) · PubMed · Cited by 77
YOSHIZUMI, M., Parker, R., Eisenach, J. C., & Hayashida, K. (2012) · Anesthesiology · doi:10.1097/aln.0b013e318254e6fd · Cited by 63
Tapentadol extended release in the management of peripheral diabetic neuropathic pain
Vadivelu, N., Maslin, B., Kai, A., Legler, A., Kodumudi, G., & Berger, J. M. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s32193 · Cited by 58
Baron, R., Allegri, M., Correa‐Illanes, G., Hans, G. H., Serpell, M. G., Mick, G., & Mayoral, V. (2016) · Pain and Therapy · doi:10.1007/s40122-016-0060-3 · Cited by 56
Drug Combinations in the Treatment of Neuropathic Pain
Eisenberg, E., & Suzan, E. (2014) · Current Pain and Headache Reports · doi:10.1007/s11916-014-0463-y · Cited by 42
Pain pharmacology: focus on opioids
Fornasari, D. (2014) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2014.11.3.165 · Cited by 25
Self-citationBellows, B. K., King, J. B., & Schauerhamer, M. B. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s74165 · Cited by 19
Feucht, C. L., Patel, D. R., & Bovid, K. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-18096-0_141 · Cited by 19
Bee, L., & Dickenson, A. H. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0226-9_14 · Cited by 17
Doxepin??s effects on chronic pain and depression: a controlled study
Hameroff, S. R., Weiss, J. L., Lerman, J. C., Cork, R. C., Watts, K. S., Crago, B. R., Neuman, C. P., Womble, J. R., & Davis, T. P. (1984) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198408000-00024 · Cited by 12
Leonardi, C., Vellucci, R., Mammucari, M., & Fanelli, G. C. (2015) · PubMed · Cited by 12
Cited by
Biological Function of Long Non-coding RNA (LncRNA) Xist
Wang, W., Min, L., Qiu, X., Wu, X., Liu, C., Ma, J., Zhang, D., & Zhu, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645647 · Cited by 248
“…system, either at the peripheral or at the central level, and are treated by first-line (include antidepressants and anticonvulsants acting at calcium channels), second-, and thirdline (include topical lidocaine and opioids) pharmacologicals (Xu et al., 2016; Fornasari, 2017; Eberlin, 2019).”
BackgroundTreating persistent pain after breast cancer surgery
Khan, J. S., Ladha, K. S., Abdallah, F., & Clarke, H. (2020) · Drugs · doi:10.1007/s40265-019-01227-5 · Cited by 57
Metadata
- Authors
- Fornasari, D.
- Venue
- Pain and Therapy
- Published
- 2017-11-24
- Volume
- 6
- Issue
- S1
- Pages
- 25-33
- ISSN
- 2193-651X (ISSN-L)
- 2193-8237
- OpenAlex
- W2770070688
- Cited by
- 258
- References
- 33
- FWCI
- 11.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.